Completed PHASE1 INTERVENTIONAL 1-arm NCT03403439

This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood

Relative Bioavailability of a Single Oral Dose of BI 1015550 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects

Sponsor: Boehringer Ingelheim

Conditions Healthy

Interventions BI 1015550 itraconazole

Updated 8 times since 2018 Last updated: Nov 14, 2025 Started: May 3, 2018 Primary completion: Jul 20, 2018 Completion: Jul 20, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03403439, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Dec 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 3 earlier versions

Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE1
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Biberach, Germany